Citigroup
BOLT icon

Citigroup’s Bolt Biotherapeutics BOLT Stock Holding History

Citigroup’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-256
Closed -$1.4K – 5966
2025
Q4 		$1.4K Buy
+256
New +$1.37K ﹤0.01% 5503
2024
Q1 		– Sell
-115
Closed -$2.58K – 5646
2023
Q4 		$2.58K Buy
+115
New +$2.24K ﹤0.01% 5401
2023
Q1 		– Sell
-2
Closed -$56 – 5517
2022
Q4 		$56 Sell
2
-23
-92% -$630 ﹤0.01% 5662
2022
Q3 		$1K Sell
25
-18
-42% -$745 ﹤0.01% 5606
2022
Q2 		$2K Sell
43
-368
-90% -$14.3K ﹤0.01% 5857
2022
Q1 		$22K Buy
411
+49
+14% +$3.3K ﹤0.01% 5094
2021
Q4 		$35K Buy
362
+220
+155% +$41.8K ﹤0.01% 5221
2021
Q3 		$36K Buy
142
+103
+264% +$29.1K ﹤0.01% 4913
2021
Q2 		$12K Sell
39
-3
-7% -$1.22K ﹤0.01% 5562
2021
Q1 		$28K Buy
+42
New +$27.3K ﹤0.01% 5045

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's BOLT Position: Q1 2026 in Review

Citigroup sold out of Bolt Biotherapeutics (BOLT) in Q1 2026, closing a stake of 256 shares — an estimated $1.4K sold.

Citigroup first reported a position in BOLT in Q1 2021 and held it in 10 quarters. The position peaked at $36K in Q3 2021. 24 funds tracked by Wall St. Rank hold BOLT as of Q1 2026.

  • Citigroup reported no remaining Bolt Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 256 Bolt Biotherapeutics shares in Q1 2026, an estimated $1.4K.
  • Citigroup first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 10 quarters.
  • Citigroup's Bolt Biotherapeutics position peaked at $36K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.